Anti-HER2 monoclonal antibodies + ErbB2 / HER-2 / HER2/neu tyrosine kinase inhibitors & Colorectal Cancer (CRC) (Her2+)

Colorectal Cancer (CRC) (Her2+) has strong clinical evidence, particularly in the context of metastatic disease. The treatment strategy primarily involves dual HER2 blockade, which includes the use of an anti-HER2 monoclonal antibody. This antibody is combined with either another anti-HER2 antibody or a HER2-directed tyrosine kinase inhibitor.

Common combinations include Trastuzumab with either Lapatinib or Tucatinib. HER2 amplification or overexpression serves as a targetable biomarker and is found in approximately 3–5% of metastatic colorectal cancers. Current reviews and guidelines acknowledge anti-HER2 regim…